NMPA released draft guidance covering nine QC data-integrity inspection areas. ECA reported the update on May 20, 2026. The draft applies ALCOA++ across the complete data lifecycle. It addresses paper, computerized, hybrid, and contract-laboratory systems. Weak controls can undermine OOS investigations and batch-release decisions.
Why Is NMPA Targeting QC Data Integrity?
NMPA’s draft sets nine inspection areas covering data governance, ALCOA++, paper records, computerized systems, hybrid systems, contract laboratories, deficiencies, inspection methods, and examples. The guidance links QC laboratories, audit trails, and risk-based data integrity management. The problem is fragmented control across sample and data lifecycles, which can leave records incomplete, poorly secured, or difficult to reconstruct during inspections by inspectors.
Weak Data Governance Creates Wider Compliance Risks
Weak data governance can cause missing raw data, unauthorized changes, failed inspections, unreliable OOS conclusions, and delayed batch release. ALCOA++, computerized systems, and contract laboratories must support the same traceable evidence. However, NMPA’s draft offers a positive route toward clearer responsibilities, stronger audit trails, validated controls, and risk-based oversight. Companies that map data flows and correct hybrid-system weaknesses may improve inspection readiness while reducing repeat findings and compliance uncertainty globally.
Why NMPA, ALCOA++, and Audit Trails Matter to Pharma Professionals
NMPA’s draft affects QC analysts, data integrity specialists, and quality assurance professionals. Each group must understand how ALCOA++, audit trails, paper records, and hybrid systems influence laboratory evidence. Their combined controls determine whether data remains complete, secure, reviewable, and inspection-ready.
Quality Control and Laboratory Teams
Quality control analysts must capture original data contemporaneously and reconcile sample flows. Uncontrolled worksheets, missing metadata, or weak corrections can seriously undermine analytical results, OOS investigations, and final batch decisions.
- Preserve original analytical records and metadata.
- Reconcile every sample throughout laboratory workflows.
Analytical Method Validation Scientists
Method-validation scientists must use precision, recovery, concentration range, and reference-material evidence correctly. Weak models can underestimate uncertainty, obscure systematic effects, and produce methods unsuited for intended pharmaceutical decisions in practice.
- Model uncertainty across validated concentration ranges.
- Investigate divergent recovery values scientifically.
Quality Assurance Professionals
Quality assurance professionals must approve governance procedures, investigate deficiencies, and verify contract laboratory controls. Weak oversight can leave data ownership unclear and prevent reliable review before product release or inspection.
- Define data ownership across quality systems.
- Audit contract laboratories using risk assessments.
What Could Stronger Laboratory Governance Achieve?
NMPA’s nine inspection areas show that laboratory data integrity extends from creation through destruction. Stronger governance may improve ALCOA++ compliance, audit-trail review, contract testing oversight, and confidence in batch decisions. Companies should now map sample flows, assess computerized and hybrid systems, train reviewers, and remediate high-risk gaps before inspections begin.
Want to strengthen regulated data governance? Explore Pharmuni’s GMP Master Data Management course to understand master-data classifications, change control, traceability, and data integrity assessments. Apply these principles to QC laboratories, computerized systems, audit trails, and inspection-ready GMP records.